IONS

Ionis Pharmaceuticals

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

consensus rating "Strong Buy"

EPS Below Expectations

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About IONS

Ionis Pharmaceuticals, Inc.

The leader in RNA-targeted therapy and pioneering new markets and changing standards of care with its novel antisense technology

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

05/17/1991

Exchange

NASDAQ Stock Exchange

Full-time Employees

1069

Fiscal Year Ends

12-31

Website

www.ionispharma.com

Security Type

Common stock

Office address

2855 Gazelle Court, Carlsbad, CA 92010

Business

Introduction

Ionis Pharmaceuticals, Inc. is an industry leader in the invention and development of antisense drugs. Using the new drug research and development platform, the company has developed a large number of first-class drugs. Antisense technology opens a channel between genetics and medicine. With the company's efficient and prolific drug R&D platform, the company can use antisense drugs to expand the types of drugs for itself and its partners to meet a large number of drug needs. The company's strategy is to do what the company does best -- find unique antisense drugs and develop those drugs to become critical clinical value turning points. The company invents and conducts early research on new drugs, and then licenses the drugs to partners. The company maximizes the value of drugs by handing them over to leading pharmaceutical companies for late-stage development, such as Biogen Idec, Bristol-Myers Squibb Company, Genzyme, Sanofi, GlaxoSmithKline and Eli Lilly. The company's flagship product, KYNAMRO, is moving towards the market for patients with familial hypercholesterolemia. The company was founded in 1989 in California, USA.

Company Financials

EPS

IONS has released its 2025 Q1 earnings. EPS was reported at -0.93, versus the expected -1.03, beating expectations. The chart below visualizes how IONS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IONS has released its 2024 Q4 earnings report, with revenue of 226.58M, reflecting a YoY change of -30.18%, and net profit of -104.35M, showing a YoY change of -1026.51%. The Sankey diagram below clearly presents IONS’s revenue sources and cost distribution.